全文获取类型
收费全文 | 1408345篇 |
免费 | 115695篇 |
国内免费 | 3329篇 |
专业分类
耳鼻咽喉 | 18360篇 |
儿科学 | 46549篇 |
妇产科学 | 41051篇 |
基础医学 | 200737篇 |
口腔科学 | 37690篇 |
临床医学 | 125986篇 |
内科学 | 284329篇 |
皮肤病学 | 33353篇 |
神经病学 | 116843篇 |
特种医学 | 53828篇 |
外国民族医学 | 464篇 |
外科学 | 210491篇 |
综合类 | 32754篇 |
现状与发展 | 3篇 |
一般理论 | 487篇 |
预防医学 | 109989篇 |
眼科学 | 31488篇 |
药学 | 98489篇 |
1篇 | |
中国医学 | 3347篇 |
肿瘤学 | 81130篇 |
出版年
2021年 | 10844篇 |
2019年 | 11664篇 |
2018年 | 16568篇 |
2017年 | 12665篇 |
2016年 | 14257篇 |
2015年 | 15999篇 |
2014年 | 22554篇 |
2013年 | 33385篇 |
2012年 | 45369篇 |
2011年 | 47909篇 |
2010年 | 28150篇 |
2009年 | 27046篇 |
2008年 | 44306篇 |
2007年 | 46809篇 |
2006年 | 47377篇 |
2005年 | 45846篇 |
2004年 | 43736篇 |
2003年 | 41681篇 |
2002年 | 40178篇 |
2001年 | 73000篇 |
2000年 | 74524篇 |
1999年 | 61557篇 |
1998年 | 16987篇 |
1997年 | 15429篇 |
1996年 | 15581篇 |
1995年 | 14788篇 |
1994年 | 13394篇 |
1993年 | 12581篇 |
1992年 | 45839篇 |
1991年 | 43477篇 |
1990年 | 41487篇 |
1989年 | 39553篇 |
1988年 | 36183篇 |
1987年 | 35352篇 |
1986年 | 32865篇 |
1985年 | 31278篇 |
1984年 | 23829篇 |
1983年 | 20024篇 |
1982年 | 12207篇 |
1981年 | 10779篇 |
1979年 | 20700篇 |
1978年 | 14576篇 |
1977年 | 12084篇 |
1976年 | 11365篇 |
1975年 | 11619篇 |
1974年 | 13988篇 |
1973年 | 13534篇 |
1972年 | 12633篇 |
1971年 | 11469篇 |
1970年 | 10910篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
151.
Victoria A. Chang Dawn M. Meyer Brett C. Meyer 《Journal of stroke and cerebrovascular diseases》2019,28(1):163-166
Background
Acute stroke codes may be activated for anisocoria, but how often these codes lead to a final stroke diagnosis or alteplase treatment is unknown. The purpose of this study was to assess the frequency of anisocoria in stroke codes that ultimately resulted in alteplase administration.Methods
We retrospectively assessed consecutive alteplase-treated patients from a prospectively-collected stroke registry between February 2015 and July 2018. Based on the stroke code exam, patients were categorized as having isolated anisocoria [A+(only)], anisocoria with other findings [A+(other)], or no anisocoria [A?]. Baseline demographics, stroke severity, alteplase time metrics, and outcomes were also collected.Results
Ninety-six patients received alteplase during the study period. Of the 94 who met inclusion criteria, there were 0 cases of A+(only). There were 9 cases of A+(other) (9.6%). A+(other) exhibited higher baseline National Institutes of Health (NIH) Stroke Scale scores compared to A? (17 versus 7; P?=?.0003), and no additional differences in demographics or alteplase time metrics. Final stroke diagnosis and other outcome measures were no different between A+(other) and A?. Of the A+ patients without pre-existing anisocoria, 5 of 6 (83%) had posterior circulation events or diffuse subarachnoid hemorrhage.Conclusions
In this exploratory analysis, zero patients with isolated anisocoria received alteplase treatment. Anisocoria as a part of the neurologic presentation occurred in 10% of alteplase patients, and was strongly associated with a posterior circulation event. Therefore, we conclude that anisocoria has a higher likelihood of leading to alteplase treatment when identified in the presence of other neurologic deficits. 相似文献152.
Ramya C. Mosarla Muthiah Vaduganathan Arman Qamar Javid Moslehi Gregory Piazza Robert P. Giugliano 《Journal of the American College of Cardiology》2019,73(11):1336-1349
Patients with active cancer are at an increased risk of arterial and venous thromboembolism (VTE) and bleeding events. Historically, in patients with cancer, low molecular weight heparins have been preferred for treatment of VTE, whereas warfarin has been the standard anticoagulant for stroke prevention in patients with atrial fibrillation (AF). More recently, direct oral anticoagulants (DOACs) have been demonstrated to reduce the risk of venous and arterial thromboembolism in large randomized clinical trials of patients with VTE and AF, respectively, thus providing an attractive oral dosing option that does not require routine laboratory monitoring. In this review, we summarize available clinical trial data and guideline recommendations, and outline a practical approach to anticoagulation management of VTE and AF in cancer. 相似文献
153.
154.
Toshiro Hara Rony Chanoch-Myers Nathan D. Mathewson Chad Myskiw Lyla Atta Lillian Bussema Stephen W. Eichhorn Alissa C. Greenwald Gabriela S. Kinker Christopher Rodman L. Nicolas Gonzalez Castro Hiroaki Wakimoto Orit Rozenblatt-Rosen Xiaowei Zhuang Jean Fan Tony Hunter Inder M. Verma Kai W. Wucherpfennig Itay Tirosh 《Cancer cell》2021,39(6):779-792.e11
155.
156.
157.
158.
M. D. Wiles A. El-Nayal G. Elton M. Malaj J. Winterbottom C. Gillies I. K. Moppett K. Bauchmuller 《Anaesthesia》2022,77(2):143-152
Pulse oximetry is used widely to titrate oxygen therapy and for triage in patients who are critically ill. However, there are concerns regarding the accuracy of pulse oximetry in patients with COVID-19 pneumonitis and in patients who have a greater degree of skin pigmentation. We aimed to determine the impact of patient ethnicity on the accuracy of peripheral pulse oximetry in patients who were critically ill with COVID-19 pneumonitis by conducting a retrospective observational study comparing paired measurements of arterial oxygen saturation measured by co-oximetry on arterial blood gas analysis (SaO2) and the corresponding peripheral oxygenation saturation measured by pulse oximetry (SpO2). Bias was calculated as the mean difference between SaO2 and SpO2 measurements and limits of agreement were calculated as bias ±1.96 SD. Data from 194 patients (135 White ethnic origin, 34 Asian ethnic origin, 19 Black ethnic origin and 6 other ethnic origin) were analysed consisting of 6216 paired SaO2 and SpO2 measurements. Bias (limits of agreement) between SaO2 and SpO2 measurements was 0.05% (−2.21–2.30). Patient ethnicity did not alter this to a clinically significant degree: 0.28% (1.79–2.35), −0.33% (−2.47–2.35) and −0.75% (−3.47–1.97) for patients of White, Asian and Black ethnic origin, respectively. In patients with COVID-19 pneumonitis, SpO2 measurements showed a level of agreement with SaO2 values that was in line with previous work, and this was not affected by patient ethnicity. 相似文献
159.
160.
A. Montalto V. Piazza F. Albi R. Gherli C. Contento A. Palermo F. Musumeci 《Transplantation proceedings》2019,51(1):206-209